Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Capecitabine and Colorectal cancer, with related work in Oxaliplatin, Exome sequencing, Bevacizumab. Notable publications include 'Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer', 'Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma', and 'First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer'.
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
Gut microbiota dysbiosis induces neuroinflammation in major depressive disorders: mechanisms targeting the gut-brain axis
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).
Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).
Abstract CT078: First-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: Final overall survival (OS) results from the randomized, phase III ORIENT-16 trial
PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma